Quick Answer
Amylyx Pharmaceuticals, Inc. reported Diluted EPS of $1.53 per share (loss) for fiscal year 2025.
Amylyx Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.53 | +65.5% |
| 2024 | -$4.43 | -732.9% |
| 2023 | $0.70 | +120.6% |
| 2022 | -$3.39 | +74.6% |
| 2021 | -$13.35 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.37 | +65.4% | +19.6% |
| June 30, 2025 | -$0.46 | +57.0% | -9.5% |
| March 31, 2025 | -$0.42 | +76.0% | +60.7% |
| September 30, 2024 | -$1.07 | -456.7% | +0.0% |
| June 30, 2024 | -$1.07 | -445.2% | +38.9% |
| March 31, 2024 | -$1.75 | -8850.0% | -683.3% |
| September 30, 2023 | $0.30 | +132.6% | -3.2% |
| June 30, 2023 | $0.31 | +133.3% | +1450.0% |
- Amylyx Pharmaceuticals, Inc. showed an increase of +65.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Amylyx Pharmaceuticals, Inc.’s diluted eps has grown by 88.5% (from $13.35 per share (loss) to $1.53 per share (loss)).
- The most recent figure is from Amylyx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: